The Mediator complex allows communication between transcription factors and RNA polymerase II (RNAPII). Cyclin-dependent kinase 8 (CDK8), the kinase found in some variants of Mediator, has been characterized mostly as a transcriptional repressor. Recently, CDK8 was demonstrated to be a potent oncoprotein. Here we show, using a human tumor cell line, that CDK8 is a positive regulator of genes within the serum response network, including several members of the activator protein 1 and early growth response family of oncogenic transcription factors. Mechanistic studies show that CDK8 is not required for RNAPII recruitment or promoter escape. Instead, CDK8 depletion leads to the appearance of slower elongation complexes carrying hypophosphorylated RNAPII. CDK8-Mediator regulates precise steps in the assembly of the RNAPII elongation complex, including the recruitment of positive transcription elongation factor b and BRD4. Furthermore, CDK8-Mediator specifically interacts with positive transcription elongation factor b. Thus, we have uncovered a role for CDK8 in transcriptional regulation that may contribute to its oncogenic effects.
a r t i c l e s In eukaryotes, the transcription of all protein-coding genes is accomplished by a single enzyme, RNAPII. DNA-binding transcription factors and a myriad of coregulators enable activated gene transcription by RNAPII in a cell type-and signaling-specific manner. Mediator is a large protein complex found in all eukaryotes that facilitates activatordependent transcription, yet its mechanism of action is ill defined 1, 2 . Mediator is considered to be an integral part of the pre-initiation complex (PIC), which also includes the general transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH 1, 2 . The fact that Mediator interacts directly both with transactivators and with RNAPII supports the notion that it may act as a molecular bridge to facilitate activator-induced recruitment of RNAPII onto promoters [3] [4] [5] . However, recent genome-wide studies demonstrate that transcriptional activation at post-RNAPII recruitment steps is a widespread phenomenon in metazoans.
Paused RNAPII is found at the promoters of most genes induced by stress, developmental cues and various signaling events [6] [7] [8] [9] . Upon stimulus, RNAPII is released from promoters and converted into an elongation-competent form by poorly understood mechanisms. Positive transcription elongation factor b (P-TEFb) is recognized as a critical elongation factor required for most RNAPII-dependent transcription 10 . Recruitment of P-TEFb by transactivators, the viral protein Tat or the chromatin-binding protein BRD4 stimulates elongation in a number of experimental systems [11] [12] [13] . CDK9, the kinase subunit of P-TEFb, phosphorylates Ser2 of the C-terminal domain (CTD) heptad repeats (YSPTSPS) of the largest subunit of RNAPII [14] [15] [16] . CTD phosphorylation has been implicated in regulation of RNAPII elongation and in cotranscriptional processing of nascent RNAs 15, [17] [18] [19] [20] [21] [22] . CDK7, the kinase subunit of TFIIH, can phosphorylate both Ser5 and Ser7 and mediates 5′ capping of mRNAs [21] [22] [23] [24] [25] . CDK8, a Mediator-associated kinase, can phosphorylate both Ser2 and Ser5 in vitro, with a preference for Ser5 (refs. 23,25) , but its precise contribution to CTD phosphorylation in vivo remains to be determined. Notably, positive functions for Mediator at post-RNAPII recruitment steps have been documented. In mice, knockout experiments have shown that the Mediator complex subunit 23 (MED23) is required for expression of the Egr1 gene, yet the effects of MED23 depletion could not be merely explained by impaired RNAPII recruitment 26 . Within the tumor protein 53 (p53) network, Mediator is strongly recruited during activation of genes carrying paused RNAPII, such as p21 (also known as CDKN1A) and MDM2, suggesting that it acts at post-RNAPII recruitment steps at these loci 27 . The mechanisms by which Mediator may facilitate gene activation after transcription initiation remain unknown.
Multiple variants of the human Mediator complex have been isolated that can be categorized as either 'core' Mediator or CDK8-Mediator based on the absence or presence of the CDK8 submodule 1, 28 . The CDK8 submodule is composed of CDK8, cyclin C, MED12 and MED13 and has been characterized mostly as a transcriptional repressor. For example, in vitro assays show that addition of the CDK8 submodule shuts down transcription driven by several transactivators 29 . This repression is independent of CDK8 kinase activity and is likely due to disruption of Mediator-RNAPII interactions 29, 30 . In vivo, activation of retinoic acid receptor α (RARα) and CCAAT enhancer-binding protein β (C/EBP-β) target genes correlates with a switch from CDK8-Mediator to core Mediator 31, 32 . Additionally, the MED12 subunit mediates the recruitment of repressive histone methyltransferases in vivo 33 . However, several reports have shown that CDK8 can also function as a positive regulator of gene activity. In yeast, chemical genetics experiments showed that SRB10, the CDK8 ortholog, collaborates with KIN28, the CDK7 ortholog, to promote RNAPII transcription both in vitro and in vivo 34 . In human cells, CDK8 is recruited to specific p53 target genes exclusively during conditions of activation, and CDK8 depletion impairs induction of select genes within this network 27 . Recently, CDK8 was shown to positively regulate β-catenin-dependent transcription in human cells 35 . Furthermore, CDK8 can collaborate with the histone acetyltransferase hGCN5 (KAT2A) to phosphoacetylate histone H3, a mark that correlates with activation 36 .
A recent report provides several lines of evidence that establish CDK8 as a potent oncoprotein in colon cancer: (i) CDK8 amplification and overexpression is commonly observed in colon tumors, (ii) CDK8 knockdown decreases proliferation of several colon cancer-derived cell lines and (iii) CDK8 overexpression leads to focusformation, anchorage-independent growth and tumor formation in immunodeficient animals 35 . These results could be explained in part by the fact that CDK8 is required for transcriptional activation by the oncogenic transcription factor β-catenin-TCF 35, 37 . However, only a fraction of the malignant effects of CDK8 overexpression could be blocked by a dominant negative form of TCF, suggesting that CDK8 participates in other oncogenic pathways 35 . Given the prominent role of growth-factor signaling in cancer development, we hypothesized that CDK8 could have functions within the serum response network. Indeed, we found that human CDK8 is a potent positive regulator of immediate-early genes (IEGs), which are strongly transcribed within minutes of serum stimulation. Microarray experiments in human cells show that CDK8-dependent coactivation, rather than repression, is predominant within this gene network. These effects are direct, as CDK8 is strongly recruited to these genes during activation and CDK8 depletion leads to impaired RNAPII activity at these loci. We found that CDK8 is not required for recruitment of RNAPII to promoters nor for overall RNAPII promoter escape. Instead, nuclear run-on experiments show that RNAPII elongation is impaired upon CDK8 knockdown, which correlates with decreased levels of RNAPII CTD phosphorylation at Ser2 and Ser5. CDK8 regulates precise steps during the assembly of a functional elongation complex, as CDK8 depletion impairs the orchestrated recruitment of CDK7, P-TEFb and its associated factor BRD4 (refs. 13, 38) . Notably, we show that P-TEFb interacts with both the free CDK8 submodule and CDK8-Mediator, suggesting that the CDK8 submodule may help load P-TEFb at the promoters of serum response genes. Thus, our results demonstrate a new role for CDK8 in transcriptional regulation at post-RNAPII recruitment steps.
RESULTS

CDK8 is a positive regulator of serum response gene expression
To determine the role of CDK8 in the expression of serum-responsive genes, we analyzed mRNA expression using microarray technology in HCT116 colon cancer cells in which CDK8 expression was stably knocked down. shRNA-mediated depletion of CDK8 resulted in an 80-90% reduction of CDK8 mRNA and total protein levels ( Fig. 1a) . Though CDK8 is required for proliferation of multiple colon cancer cell lines, CDK8 is not amplified in HCT116 cells and has a more modest effect on their proliferation, which enabled us to perform the experiments described in this report. Expression of CDK19, a CDK8 paralog also associated with Mediator 28 , was not affected by our shRNA (Supplementary Fig. 1a ). We identified 29 transcripts that were upregulated >2-fold after 30 min of serum stimulation in wild-type cells. Roughly 90% (26/29) of these IEGs were expressed at significantly lower levels (<50%) in serum-stimulated shCDK8 cells ( Fig. 1b) . Only three serum-responsive genes (THBS1, PLK2 and KLF6) were expressed at higher levels in shCDK8 cells. A number of IEGs, such as members of the AP-1 and EGR families of transcription factors, stood out (FOS, JUN, FOSB, JUNB, EGR1, EGR2 and EGR3). Notably, these are potent oncogenes acting downstream of the MAPK pathway that are activated by the ubiquitous serum response factor (SRF) and by Ets-like transcription factors, such as ELK1 (ref. 39 ). Validation of microarray results by Q-RT-PCR showed that CDK8 depletion leads to decreased expression of all genes analyzed over multiple time points ( Fig. 1c and Supplementary Fig. 1b ). Of note, the effect of CDK8 knockdown is more drastic during early time points, when increased gene expression is driven by transcriptional activation and is less influenced by subsequent transcriptional shutdown and mRNA degradation. The effects of CDK8 knockdown on IEG expression are not due to off-target effects of a particular shRNA sequence, because reduced expression of IEGs is also observed when a different sequence within the CDK8 mRNA is targeted ( Supplementary Fig. 1c ).
CDK8 is required for RNAPII CTD phosphorylation
To test whether the impact of CDK8 on IEG mRNA expression is due to a direct role of CDK8 in transcriptional activation at these a r t i c l e s a r t i c l e s loci, we performed chromatin immunoprecipitation (ChIP) assays for CDK8, total RNAPII and two phosphorylated isoforms of RNAPII. ChIP analysis of CDK8 showed that before stimulation, there is little to no CDK8 at the promoters of FOS and EGR1, EGR2 and EGR3. However, serum treatment of wild-type cells produces a strong increase in CDK8 recruitment (7-to 14-fold) (average data for FOS, EGR1, EGR2 and EGR3 are shown in Fig. 2 ; statistical analysis is shown in Supplementary Fig. 2 ). As expected, CDK8 occupancy decreases ~80% in shCDK8 cells across the loci studied. ChIP analysis indicates that CDK8 was not required for the recruitment of RNAPII to all four IEGs but did have a positive effect on CTD phosphorylation ( Fig. 2) . RNAPII is preloaded at the FOS proximal promoter with only a small increase in occupancy after serum treatment. However, a clear increase in RNAPII was observed at the FOS and EGR1 intragenic regions during activation, indicative of enhanced elongation. Notably, CDK8 knockdown did not have substantial effects on total RNAPII occupancy at any of the locations tested, before or after activation. This was more evident at the nonpreloaded EGR2 and EGR3 genes, which showed a sharp increase in RNAPII occupancy at their proximal promoters upon serum treatment (~4-to 7-fold) that was refractory to CDK8 depletion ( Fig. 2) . RNAPII CTD phosphorylation at Ser5 and Ser2 is linked to promoter clearance and elongation 14, 15 . Accordingly, both phosphorylation marks increased sharply upon activation at IEGs in wild-type cells. Typically, Ser5 phosphorylation peaks near the transcription start site, whereas Ser2 phosphorylation accumulates at the 3′ end of genes 18 . Depletion of CDK8 clearly reduced the level of Ser5 phosphorylation (S5P) at all three EGR genes; however, the effects on FOS are less pronounced. More strikingly, CDK8 knockdown strongly reduced the level of phospho-Ser2 (S2P) at all four genes ( Fig. 2) . Notably, CDK8 knockdown did not affect cellular levels of either mark as measured by western blot (Supplementary Fig. 3a) , indicating that the effects of CDK8 on CTD phosphorylation are gene specific rather than global. Of note, CDK8 knockdown did not affect mRNA expression or RNAPII activity at the housekeeping gene GAPDH (Supplementary Fig. 3b,c) . In summary, our results indicate that CDK8 is playing a role in transcriptional activation events subsequent to recruitment of RNAPII at serumresponsive loci.
CDK8 affects the rate of transcriptional elongation at IEGs
Intriguingly, our ChIP analysis did not detect significant differences in RNAPII occupancy within IEGs intragenic regions, yet we observed clear effects on CTD phosphorylation and mRNA steady-state levels. CTD phosphorylation is known to affect both RNAPII elongation and cotranscriptional RNA processing. To investigate the impact of CDK8 depletion on these events, we first measured the levels of unprocessed primary transcripts using PCR primers amplifying intronic regions. Clearly, CDK8 depletion caused a sharp decrease in the levels of FOS and the EGR pre-mRNAs produced upon serum stimulation ( Fig. 3a) , suggesting that the CDK8-dependent effects on CTD phosphorylation result in a defect in the rate of transcription rather than cotranscriptional RNA processing. To test this, we performed nuclear run-on assays in conditions that prevent reinitiation. We treated serum-starved cells with serum for 10 min before we stalled active elongation complexes and isolated the nuclei. We then allowed transcription to progress for either 5 or 60 min before nuclei were lysed. Analysis of primary transcripts generated during the run-on shows that at the 5-min time point RNA levels of FOS, EGR1, EGR2 and EGR3 were 2-to 20-fold higher in control cells as compared to shCDK8 cells; however, by the 60-min time point, RNA levels were either equivalent or much more similar (Fig. 3b) . This provides strong evidence that CDK8 positively affects the actual rate of transcription: although RNAPII still elongates in CDK8-depleted cells, it does so at a slower pace.
CDK8 is required for assembly of elongation complexes
In agreement with the fact that CDK8 plays no role in RNAPII recruitment, we found that CDK8 depletion did not affect recruitment or activation of the key transactivators acting at the FOS promoter. The SRF-ELK1 complex is constitutively bound to the chromatin of its target genes and is activated by MAPK-dependent phosphorylation 39 . Phosphorylation of the CTD of ELK1 has been shown to be important for the allosteric stimulation of histone acetyltransferase (HAT) activities 40 . CDK8 depletion did not affect the levels of chromatin-bound Fig. 4 ; statistical analysis is shown in Supplementary Fig. 4) . Likewise, we did not observe differences in ELK1 phosphorylation or overall histone acetylation (AcH4) (Fig. 4a) . As expected, CDK8 did not affect the chromatinbound levels of PIC components involved in RNAPII recruitment, such as TBP or TFIIB (Fig. 4a) .
It has been demonstrated that phosphorylation of ELK1 triggers association with the MED23 subunit of Mediator and that MED23 is required for activation of certain ELK1 target genes 41 . Our ChIP analysis confirms that MED23 is recruited to FOS and EGR1 upon serum stimulation ( Fig. 4b) . Notably, the levels of chromatin-bound MED23 are decreased by roughly 50% in CDK8 knockdown cells, suggesting that CDK8 helps to stabilize Mediator association at these loci. This notion is supported by the fact that two other Mediator subunits, MED1 and MED12, also show decreased association to the FOS and EGR1 promoters upon CDK8 depletion (Fig. 4b) . Whereas CDK8 knockdown may have a modest effect on MED12 stability, it does not decrease the cellular pools of MED23 and MED1 (Supplementary Fig. 3a) .
Given the clear effects of CDK8 knockdown on RNAPII CTD phosphorylation and elongation rates at IEGs, we next focused on complexes containing CTD kinases. We found that recruitment of both CDK7 and CDK9 to the FOS and EGR1 loci is impaired upon CDK8 knockdown (average data for FOS and EGR1 are shown in Fig. 5 ; statistical analysis is shown in Supplementary Fig. 5) . In contrast to that of CDK7 and CDK9, the recruitment of other factors regulating RNAPII pausing and elongation, such as negative elongation factor (NELF), 5,6-dichloro-1-β-dribofuranosylbenzimidazole (DRB) sensitivity-inducing factor (DSIF) and facilitates chromatin transcription (FACT), is not affected by CDK8 knockdown. NELF and DSIF (a dimer of SPT4 and SPT5) are key regulators of RNAPII pausing at promoters 42, 43 . Upon promoter escape, SPT5 associates with RNAPII and functions as a positive elongation factor 43, 44 . FACT (a dimer of SSRP1 and SPT16) is another positive regulator of elongation required for transcription-coupled nucleosome remodeling 45 . Our ChIP analysis demonstrated that NELF-A and SPT5 occupy the FOS promoter carrying preloaded RNAPII. Upon activation, NELF-A remains at the transcription start site, whereas SPT5 associates with the intragenic region. In contrast, SPT16 is recruited strongly to the gene body upon serum treatment (Fig. 5) . Occupancy profiles for all three factors are unaffected by CDK8 depletion during both basal and stimulated conditions. These results indicate that CDK8 orchestrates key events in the formation of a functional elongation complex: namely, recruitment of CDK7 and CDK9 and subsequent RNAPII CTD phosphorylation. a r t i c l e s
CDK8 depletion impairs BRD4 recruitment
The bromodomain protein BRD4 has been recently implicated in recruitment of P-TEFb to several human genes 38, 46 . BRD4 interacts both with acetylated histones and with P-TEFb, thus linking chromatin modifications to elongation control. Importantly, several reports have described an interaction between BRD4 and Mediator, yet the relevance of this interaction has not been defined 38, [47] [48] [49] . Our ChIP analyses show that BRD4 is strongly recruited to FOS and EGR1 upon serum stimulation with a profile similar to those of CDK9 and Mediator. Notably, BRD4 recruitment was significantly decreased upon CDK8 knockdown. Strikingly, our detailed analysis of histone acetylation at FOS and EGR1 indicates that BRD4 recruitment is most likely a result of its interaction with Mediator rather than its association with the acetylated lysines previously described to be recognized by its double bromodomain. Previous work led to the conclusion that BRD4 detects histone H4 acetylated at Lys5, Lys8 and Lys12 (ref. 46) . In contrast, other previous work led to the conclusion that BRD4 instead binds histone H4 acetylated at Lys16 and histone H3 acetylated at Lys9 (ref. 38) . Our ChIP analyses using antibodies against tetra-acetyl H4 (Lys5, Lys8, Lys12 and Lys16), acetyl H4-K8 (H4 K8Ac), acetyl H4-K12 (H4 K12Ac), acetyl H4-K16 (H4 K16Ac) and acetyl H3-K9 (H3 K9Ac) show that none of these marks is affected by CDK8 knockdown and that the occupancy profiles of these marks do not resemble that of BRD4 (Figs. 4a and 5a and Supplementary Figs. 5 and 6) .
CDK9 inhibition reproduces the effects of CDK8 knockdown
Our results indicate that many of the effects of CDK8 knockdown on RNAPII activity at postrecruitment steps could be explained by decreased P-TEFb recruitment. To test for the impact of CDK9 activity on IEG activation, we used the pharmacological inhibitor flavopiridol 10 . Pretreatment of cells with flavopiridol (150 nM)
prevented serum-induced mRNA accumulation of FOS, EGR1, EGR2 and EGR3 (Fig. 6a) . ChIP analysis shows that CDK9 inhibition did not decrease the levels of promoter-bound RNAPII at IEGs carrying preloaded RNAPII (for example, EGR1) or at those showing induced RNAPII recruitment (for example, EGR2) ( Fig. 6b) . Clearly, inhibition of CDK9 by flavopiridol had a more pronounced effect on RNAPII occupancy at intragenic regions than did CDK8 depletion, which could be explained by the fact that some amount of P-TEFb is still recruited to these loci in CDK8 knockdown cells. However, a small but significant amount of intragenic RNAPII was still detected in flavopiridol-treated cells. These RNAPII complexes presumably elongate at low rates, preventing significant mRNA accumulation. As expected, flavopiridol treatment completely blocked RNAPII CTD phosphorylation in Ser2. Flavopiridol also a r t i c l e s blocked Ser5 phosphorylation in intragenic regions but had no effect on promoter-proximal Ser5 phosphorylation. Overall, these results suggest that decreased CDK9 activity at IEGs upon CDK8 depletion could explain the postrecruitment defects observed in CDK8 knockdown cells.
CDK8-Mediator interacts with P-TEFb
A role for Mediator in recruitment of TFIIH has already been described in other systems 50 , which could explain the reduced association of CDK7 with IEG promoters upon CDK8 depletion. However, it is unclear how CDK8-Mediator may affect P-TEFb recruitment. At least two variants of the human Mediator complex exist within the cell nucleus 1 . CDK8-Mediator complexes contain the CDK8 submodule and are devoid of the MED26 subunit, which is unique to 'core' Mediator, whereas the MED1 subunit is found in both. We have previously reported that a large fraction of the CDK8 submodule exists separately from core Mediator 51 . Serendipitously, research efforts to identify factors interacting with Mediator showed that P-TEFb associates specifically with CDK8-Mediator. In these experiments, we used antibodies against CDK8 or MED1 to immunoprecipitate Mediator from nuclear extracts. After a series of high-salt washes, we eluted and identified bound proteins using MudPIT methodology (samples shown in Fig. 7a) . Notably, multiple peptides for CDK9 and cyclin T were detected in the CDK8 IP but not in the MED1 IP (C.C.E. and D.J.T., unpublished results). These results were confirmed by quantitative western blot experiments (Fig. 7b) . As expected, subunits of the CDK8 submodule (MED12, MED13 and cyclin C) are enriched in the CDK8 IP, whereas MED26 was not detected in these CDK8 IP samples. In agreement with several independent reports 38, [47] [48] [49] , we also observed an association of BRD4 with Mediator. Notably, and in agreement with previous work 48 , we found that BRD4 associated with Mediator regardless of the presence of the CDK8 submodule.
Notably, quantitative western blotting clearly shows enrichment of the P-TEFb subunits CDK9 and cyclin T1 in the CDK8-Mediator sample (Fig. 7b) .
To investigate whether P-TEFb interacts with CDK8-Mediator and/ or the free CDK8 submodule, we tested for the presence of CDK9 in fractions enriched for these complexes via biochemical fractionation. Using purification methods previously described 51 , we found that CDK9 copurifies with both CDK8-Mediator and the free CDK8 submodule (Fig. 7c) . These results suggest that the CDK8 submodule may facilitate association of P-TEFb with the rest of Mediator to regulate CTD phosphorylation and transcriptional elongation at specific gene loci such as the IEGs studied here.
DISCUSSION
The CDK8 submodule of Mediator is a pleiotropic regulator of gene expression. On one hand, this protein complex has been characterized as a transcriptional repressor that inhibits RNAPII by multiple mechanisms, including (i) kinase-independent allosteric regulation of Mediator-RNAPII interactions 29 , (ii) kinase-dependent inactivation of TFIIH via phosphorylation of its cyclin H subunit 52 and (iii) gene silencing via recruitment of histone methyltransferases 33 . On the other hand, several reports indicate that CDK8 is a positive regulator of gene activity in other scenarios. In yeast, SRB10 promotes RNAPII activity in vitro and in vivo 34 . In human cells, CDK8 depletion impairs activation of genes responsive to p53 and β-catenin 27, 35 . Additionally, CDK8-Mediator complexes can perform histone modifications associated with gene activation 36 . In this report, we provide evidence that CDK8 is a direct positive regulator of transcription within the serum response network. We found that CDK8 is dispensable for RNAPII recruitment to promoters carrying preloaded RNAPII (FOS, EGR1) as well as promoters showing inducible RNAPII recruitment (EGR2, EGR3). Furthermore, CDK8 depletion did not produce a drastic impairment in RNAPII escape from promoter regions, as we detected significant amounts of RNAPII throughout the intragenic regions of these genes upon activation. Instead, decreased IEG expression in CDK8 knockdown cells is explained by the appearance of slower elongation complexes containing hypophosphorylated RNAPII. The findings in this report represent a marked advance in our understanding of how CDK8 promotes gene activity but also prompt more general questions about the role of CTD phosphorylation, CTD kinases and Mediator in mammalian gene-expression control.
Here we establish a strong correlation between CDK8 status, CTD phosphorylation and RNAPII elongation rates. Although some effect of CDK8 depletion on IEG RNA processing cannot be fully ruled out, our results indicate that most of the negative effects of CDK8 knockdown on IEG expression are explained by decreased elongation rates. In nuclear run-on experiments, CDK8 depletion decreased elongation rates by 50-75% at the FOS locus and >90% at the EGR loci. Notably, these differences were attenuated when additional time was allowed for elongation complexes derived from CDK8depleted cells to proceed, with the FOS locus showing equivalent RNA synthesis and the EGR loci reaching up to 30-60% of wild-type levels by 60 min. Interestingly, the impact of CDK8 on CTD phosphorylation is more pronounced at the EGR loci, further supporting a link between CTD phosphorylation and elongation rates. The notion that decreased transcription, rather than impaired processing, causes lower IEG mRNA expression in CDK8-depleted cells is reinforced by the fact that these cells accumulate lower levels of pre-mRNAs. Despite the fact that CDK8 is a CTD kinase and its depletion leads to hypophosphorylated CTD and slower elongation complexes, a simple interpretation of these results is complicated by the fact that recruitment of two other CTD kinases, CDK7 and CDK9, was impaired by CDK8 depletion. Until recently, the prevalent view on CTD phosphorylation maintained that CDK7 was the major Ser5 kinase and CDK9 the predominant Ser2 kinase. This view originated with the early characterization of CDK7 and the CDK9-like kinases in yeast 16, 53 . However, recent chemical genetic experiments in yeast and human cells have shown that inhibition of CDK7 kinase activity does not result in global defects in Ser5 phosphorylation 24, 54, 55 ; instead, CDK7 may be the major kinase for Ser7, an alternate phospho-acceptor site within the CTD 24, 56 . Interestingly, CDK9 may be a relevant Ser5-kinase in certain contexts 57, 58 . CDK8 is known to phosphorylate both Ser2 and Ser5 in vitro 23 , but its in vivo contributions remain unknown. Interplay between the CTD kinases is supported by the fact that Ser5 phosphorylation by CDK7 'primes' the CTD for subsequent Ser2 phosphorylation by CDK9 (ref. 59) . Yeast Mediator was shown to be required for TFIIH recruitment to specific promoters and our data suggest that a similar interaction between CDK8-Mediator and TFIIH may also take place at IEGs 50 . Additionally, our data indicate that P-TEFb association with the RNAPII machinery is also facilitated by CDK8-Mediator and we provide evidence of a physical interaction between the two complexes.
Though much is known regarding the critical role of P-TEFb in elongation control, little is known about the mechanisms by which this complex is recruited to allow for gene-specific regulation. Several modes of P-TEFb recruitment have been described, including direct interactions with DNA-binding proteins or with the bromodomain protein BRD4 (refs. 13,38,48,49,60) . Interestingly, BRD4 has been shown repeatedly to interact with Mediator, and our results confirm this interaction. Furthermore, our results agree with those of previous work 48 , which found that BRD4 associates with both CDK8-Mediator and core Mediator 48 . In contrast, we find that P-TEFb associates preferentially with CDK8-Mediator and the free CDK8 submodule. These observations suggest that BRD4 and P-TEFb interact with Mediator by different means.
Early evidence that Mediator regulates RNAPII activity at postrecruitment steps was demonstrated previously 26 . Using MED23-null (MED23 -/-) mice, it was found that abolishing Mediator recruitment to the EGR1 locus drastically impairs transcriptional activation without affecting binding of TFIIA, TFIID, histone acetylation, methylation or association of the chromatin remodeling factor BRG1. Notably, the defects in EGR1 transcription observed in MED23 −/− cells could not be explained merely by reduced RNAPII association, as a significant fraction of RNAPII remained associated with the promoter in mutant cells. Thus, it was concluded that Mediator affects both the recruitment and postrecruitment steps. Given that RNAPII occupancy remains unaffected in CDK8 knockdown cells, we have been able to more clearly define the contribution of Mediator to postrecruitment steps. A significant fraction of MED23 remains associated with the promoter upon CDK8 depletion, which may explain why we did not observe any recruitment defects. Instead, most effects of CDK8 knockdown on IEG expression can be explained by impaired P-TEFb recruitment. This notion is supported by the fact that CDK9 inhibition by flavopiridol resembles (albeit with more penetrance) the effects of CDK8 knockdown. Given past results that show mutually exclusive association of CDK8 submodule and RNAPII with Mediator 28,29 , our data further suggest dynamic association of the CDK8 submodule at the promoter of active serum response genes. Taken together, these results invoke a mechanism involving CDK8 submodule exchange at the promoter to regulate RNAPII and P-TEFb association within the transcriptional apparatus at postrecruitment steps.
CDK8 is a potent oncogene in colon cancer. CDK8 overexpression promotes cell proliferation, anchorage-independent growth and tumor growth in xenografts 35 . Part of these effects can be attributed to the fact that CDK8 promotes transcription mediated by the oncogenic transcription factor β-catenin-TCF 35 . Here, we report that CDK8 is a potent positive regulator of the serum response network, which has been implicated in multiple tumorigenic phenotypes. Understanding of the precise contributions of the β-catenin and serum response networks to the overall oncogenic effects of CDK8 overexpression awaits further experimentation. Whereas the transformation-inducing effects of β-catenin can be effectively blocked by overexpression of a dominant negative version of its binding partner TCF 35 , the accomplishment of the equivalent task for the serum response network is not straightforward. Upon serum stimulation, ERKs translocate to the nucleus and activate a myriad of transcription factors, including multiple members of the Ets family, MYC and C/EBP-β 39 . Possible functional redundancy within the Ets family will impose a combinatorial genetic approach to determine their precise interaction with CDK8 during tumor development. Nonetheless, the fact that many MAPK-regulated transcription factors and their target genes have well-demonstrated roles in the development of cancer will make this a worthy task that would lead to a detailed understanding of the oncogenic effects of CDK8 overexpression.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
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The microarray data has been deposited under accession code GSE19199.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
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